CELL & GENE THERAPY INSIGHTS

Spotlight

Cellular immuno-oncology – overcoming manufacturing and development obstacles to commercial success

Jun 2021
Guest Editor:
Fritz Fiesser, Director, C&GT Engineering and Informatics at GlaxoSmithKline
Fritz Fiesser
Director, C&GT Engineering and Informatics at GlaxoSmithKline

Innovator Insight

Navigating regulations: novel cell therapy platforms and their path to clinical manufacturing

Nina Bauer,
Natika Calhoun,
Anthony Davies,
Matthew Muldoon
11 August 2021
Innovator Insight

CMC obstacles in cell and gene therapy: four solutions to solve six challenges

Subbu Viswanathan,
Marc Puich
10 May 2021
Innovator Insight

Commentary

Towards the rational design of a next-generation dendritic cell vaccine for cancer immunotherapy

Marcelo Bravo,
Timothy J Davies,
Paul J Fairchild
8 June 2021
Commentary

Interview


Viewpoint

Allogeneic T-cell therapies: from R&D lab to production facility

Jakob Dupont, M.D.,
Joe Newell
9 June 2021
Viewpoint

Report

Other articles

Webinars

From first collection to commercial launch: Streamlining your supply chain to support next generation therapies

From first collection to commercial launch: Streamlining your supply chain to support next generation therapies

Chris McClain
Chris McClain, Head of Business Development & Sales at Be The Match BioTherapies
Aileen Baquiran
Aileen Baquiran, Senior Director, Business Operations
6 May 2021
Webinar
Applying Warp Speed lessons to your ATMP manufacturing facility

Applying Warp Speed lessons to your ATMP manufacturing facility

James Bornholdt
James Bornholdt, Director, SlateXpace Technical Operations at CRB
Charles Heffernan
Charles Heffernan, Director at CRB
Thomas Page
Thomas Page, Vice President - Engineering & Asset Development at Fujifilm Diosynth Biotechnologies
Jarrod Wrampe
Jarrod Wrampe, Process Utility Engineer at CRB
12 May 2021
Webinar
Navigating regulations - novel cell therapy platforms and their path to clinical manufacturing

Navigating regulations - novel cell therapy platforms and their path to clinical manufacturing

Nina Bauer
Nina Bauer, Head of Commercial, Gene Editing and Novel Modalities, Merck KGaA
Natika Calhoun
Natika Calhoun, Regulatory Consultant, Merck KGaA
Anthony Davies
Anthony Davies, Founder and CEO, Dark Horse Consulting
Matt Muldoon
Matt Muldoon, Senior Director, Supplier Management, Allogene Therapeutics
27 May 2021
Webinar
Applying a closed, modular, semi-automated system to CAR T cell therapy manufacturing

Applying a closed, modular, semi-automated system to CAR T cell therapy manufacturing

Yongchang Ji
Yongchang Ji, Manager of Product Applications, Cell and Gene Therapy, Thermo Fisher Scientific
Semsi Ensari, PhD
Semsi Ensari, PhD, Senior Director, Kite Pharma
Nathan Moore, PhD
Nathan Moore, PhD, Associate Director, Engineering & Automation Cell Therapies, Pharmaceutical Sciences, Takeda
29 June 2021
Webinar
Accelerating CAR-T process development: The power of process insight

Accelerating CAR-T process development: The power of process insight

Julia Hupfeld, Ph.D.
Julia Hupfeld, Ph.D., Advanced Therapies Expert, Sartorius
29 July 2021
Webinar